Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 14/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151532 | 0.94 | ITGA4 (0.50) | ITGA4ALDH1A1LMNASMN1; SMN2ITGB1 | |
| SCHEMBL6544076 | 0.91 | ITGA4 (0.57) | ITGA4ALDH1A1LMNASMN1; SMN2ITGB1 | |
| SCHEMBL6544236 | 0.91 | ITGA4 (0.57) | ITGA4ALDH1A1LMNASMN1; SMN2ITGB1 | |
| SCHEMBL5152442 | 0.91 | ITGA4 (0.57) | ITGA4SMN1; SMN2ITGB1KMT2AGAA | |
| SCHEMBL6212266 | 0.91 | ITGA4 (0.58) | ITGA4ALDH1A1LMNASMN1; SMN2ITGB1 | |
| SCHEMBL5149789 | 0.91 | ITGA4 (0.49) | ITGA4ALDH1A1LMNASMN1; SMN2ITGB1 | |
| SCHEMBL5149716 | 0.88 | ITGA4 (0.47) | ITGA4ALDH1A1LMNASMN1; SMN2ITGB1 | |
| SCHEMBL6543408 | 0.88 | ITGA4 (0.55) | ITGA4SMN1; SMN2ITGB1KMT2AGAA | |
| SCHEMBL6544253 | 0.87 | ITGA4 (0.49) | ITGA4ALDH1A1LMNAITGB1PYGL | |
| SCHEMBL5153501 | 0.85 | ITGA4 (0.49) | ITGA4ALDH1A1LMNASMN1; SMN2ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ITGA4 4/4885ALDH1A1 120/4885LMNA 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.